📈 Stock
Lexicon Pharmaceuticals, Inc.'s obesity drug, LX9851, is the subject of an exclusive license agreement with Novo Nordisk worth up to $1bn.
Onyx @ Union Square: Mike Exton, CEO, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Related
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?